# IMbrave050 (NCT04102098)

> A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04102098
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Hepatocellular
- Interventions: Atezolizumab; Bevacizumab
- Enrollment: 668
- Primary outcome: Recurrence-Free Survival (RFS), as Determined by IRF

## Commentary we found

- X threads: 84
- Podcasts: 40
- YouTube: 31
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imbrave050-nct04102098

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04102098", "email": "<work email>"}; the inbox owner confirms by the emailed link.